Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.54 - $113.51
Previous CloseN/A
Volume65.93K
Average Volume (3M)507.80K
Market Cap
$5.59B
Enterprise Value$904.48M
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 07, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding66,373,510
10 Day Avg. Volume479,651
30 Day Avg. Volume507,798
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-52.46
Price to Sales (P/S)0.00
P/FCF Ratio-93.92
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$111.25Price Target Upside42.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Nuvalent News
PremiumCompany Announcements
Nuvalent Board Member Emily Conley Resigns
PremiumCompany Announcements
Nuvalent, Inc. Reports Q1 2025 Financial Results
Bulls Say, Bears Say
Bulls Say
FDA ApprovalNUVB's Ibtrozi (Taletrecinib) receives FDA approval, setting a competitive bar for likely best-in-class ROS1 inhibitor Zidesamtinib.
Financial PerformanceThe company reported cash and cash equivalents of $1.1 billion, which they estimate will provide a cash runway into 2028.
Preclinical DataNuvalent presented preclinical crystal structure data on zidesamtinib versus SOC therapies at the 2025 annual meeting of the American Association for Cancer Research (AACR), indicating favorable binding of the drug to G2032R-mutant ROS1, the most frequent ROS1 substitution that confers resistance to TKI therapy.
Bears Say
Competitive ConcernsOngoing KOL conversations highlight a likely future preference for Zidesamtinib once NUVL's drug also receives potential approval.
Market SkepticismInvestors are generally skeptical about the commercial ROS1 opportunity given a number of agents that have had limited success.
Safety And Efficacy ConcernsFDA approval of Taletrecinib is consistent with expectations and represents a competitive bar that is potentially surpassable on efficacy and very likely surpassable on safety.
Ownership Overview
32.71% Insiders
22.78% Mutual Funds
<0.01% Other Institutional Investors
33.57% Public Companies and Individual Investors
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $55.53 and its highest was $113.51 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $5.59B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Aug 07, 2025 which is in 53 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on May 08, 2025. The company reported -$1.18 earnings per share for the quarter, missing the consensus estimate of -$1.097 by -$0.083.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.23.
How many shares outstanding does Nuvalent have?
Nuvalent has 66,373,510 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.18 in its last earnings report, missing expectations of -$1.097. Following the earnings report the stock price went up 7.314%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
Nuvalent Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$111.25 (42.19% Upside)
$111.25 (42.19% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $110.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.93%
12-Months-Change
Fundamentals
Return on Equity
-35.69%
Trailing 12-Months
Asset Growth
56.08%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$111.25
▲(42.19%Upside)
Technical Analysis
Blueprint Medicines
―
Axsome Therapeutics
―
Verona Pharma
―
Krystal Biotech
―
Revolution Medicines
―